Crackdown on Vapes Falling Short, Report Finds

Why It Matters

The weak enforcement enables a flood of unapproved, youth‑targeted vapes, undermining public‑health goals and FDA mandates to curb nicotine addiction among minors.

Key Takeaways

• DOJ took 88 enforcement actions on illegal e‑cigs (2022‑2025).
• Only 41 of 6,000 U.S. e‑cig products cleared by FDA.
• Seizures captured 6 million vapes, just 4% of Chinese exports.
• 1.6 million U.S. youths still use e‑cigarettes despite bans.
• Federal task force launched 2024 to target distributors and retailers.

Pulse Analysis

The GAO’s latest assessment shines a light on a regulatory paradox: while the U.S. market for e‑cigarettes has exploded, federal enforcement has struggled to keep pace. Between 2022 and 2025, the Justice Department recorded just 88 enforcement actions, a modest figure given the estimated 6,000 vaping products circulating nationwide. This disparity reflects broader challenges in aligning agency resources with a rapidly evolving retail landscape that blends online storefronts, gas‑station kiosks, and specialty vape shops. The report underscores how limited actions—primarily adding sellers to a blacklist—have done little to stem the tide of illicit products.

The public‑health stakes are stark. The CDC estimates 1.6 million American children still vape, a figure that persists despite aggressive seizures by the FDA and Customs, which confiscated more than 6 million units from 2024‑2025. Yet even a high‑profile seizure of 3 million vapes worth $76 million accounted for only 4% of China’s monthly export volume, illustrating the scale of the supply chain gap. Most illegal devices are flavored to appeal to younger users, a tactic that sidesteps existing flavor bans and fuels nicotine addiction among a vulnerable demographic.

Policymakers are now weighing a more coordinated response. A federal task force launched in 2024 aims to shift focus from end‑point retailers to the distributors that supply them, a strategy experts argue could disrupt the supply chain more effectively. Strengthening DOJ resources, tightening FDA pre‑market approval processes, and enhancing cross‑agency data sharing are cited as critical levers. As the market continues to expand, decisive action will be essential to protect public health and fulfill congressional mandates on youth nicotine exposure.